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Summary Points
• Adherence to prescribed treatment remains a critical component of clinical trials in
tuberculosis (TB) treatment. Recent evidence indicates that adherence strongly influ-
ences the outcome of therapy; attention to its quantification and measures to assure its
implementation should increase.
• In the context of a World Health Organization (WHO) Technical Consultation on
“Advances in Clinical Trial Design for Development of New TB Treatments,” we
reviewed the challenges related to adherence confronting the trials community.
• We discuss the importance of adherence to therapy in TB clinical trials, consider several
definitions and measures of adherence, comment on the standard provided by directly
observed therapy (DOT), and briefly review evolving electronic methods for the assess-
ment of adherence.
• Adherence affects both the outcome of therapy and the risk of acquired drug resistance.
Assessment of adherence should consider not only overall adherence but also the timing
and intensity of nonadherence.
• Appropriate methods for pooling and analyzing electronic data on adherence are
needed.
• Better methods are needed for linking information on adherence to individual pharma-
cokinetics and pharmacodynamics and to individual patient outcomes.
Introduction
Medication adherence remains the most underrated and understudied factor affecting the out-
come of tuberculosis (TB) therapy. Its importance has been appreciated since the time of the
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initial South India trial conducted by the Tuberculosis Research Center and the British Medi-
cal Research Council (MRC), comparing in-patient and domiciliary treatment [1]. Twenty-
five years later, Fox wrote “It is paradoxical to insist on the importance of 100% success with
primary chemotherapy and to use self-administered chemotherapy as a means of achieving it”
[2]. In their 1999 encyclopedic review of the MRC TB trials, Fox, Mitchison, and Ellard
reported that a common feature of those trials was “the effort made [including hospitalization
for the full treatment] to ensure that the patients actually took the prescribed regimen through-
out the trial period” [3]. These examples illustrate the importance of adherence to treatment
for the validity of a clinical trial and for the success of individual and programmatic care.
Despite the clear and obvious need to ensure optimal treatment adherence, "full supervision,"
in the form of directly observed therapy (DOT) as currently delivered, has not consistently
been associated with improved outcomes. Thus, significant challenges persist in measuring
and maximizing adherence with antituberculosis therapy; recent data and analyses provide
evidence that the absence of full adherence in TB trials has important implications for TB regi-
men development and for the durability of new regimens. In March 2018, the World Health
Organization (WHO) held a Technical Consultation on Advances in Clinical Trial Design for
Development of New TB Regimens, which is the topic of the Collection of which this paper is
part [4]. In this context, we reviewed the importance of treatment adherence, the implications
of a drug or regimen’s “forgiveness for missed doses,” and emerging novel approaches to mea-
suring and maximizing adherence in clinical trials and in patient care.
Importance of adherence
Adherence affects patient outcomes and is thus an important factor to consider when evaluat-
ing regimens in clinical trials. Differing adherence across treatment arms could potentially
lead to misleading conclusions about treatment arm performance. For example, consider (as a
hypothetical example) a study with poor adherence in the control arm but perfect adherence
in the experimental arm. If the goal of a study is to measure the efficacy of a new regimen, the
relatively poor adherence in the control arm will give an overly optimistic estimate of the
improvement in outcomes with the experimental treatment. However, if the goal of the study
is to evaluate effectiveness (i.e., performance under real-word conditions), the relative differ-
ence in adherence may accurately reflect the real-word difference in the 2 regimens. One com-
plication is that the level of adherence may vary widely across different populations and
cultural or economic settings, raising concerns about whether estimates of effectiveness are
broadly generalizable. The relation of adherence to regimen effectiveness (the usual target out-
come of “pragmatic” trials) in trial versus program settings was noted nearly 50 years ago and
continues to challenge the generalizability of trial findings [5].
Adherence may have a substantial impact on the interpretation of clinical trial findings.
Adherence is often an active choice by each patient on how to comply with the assigned ther-
apy. Adjustments in analysis based on observed adherence may alter the balance introduced
by randomization. Restricting analyses only to those with high adherence focuses on a subset
of the population that may have fundamentally different risk than those who are not adherent.
A classic example of this circumstance is provided by the Coronary Drug Project trial assessing
a lipid-lowering drug in men with recent myocardial infarction: participants with good adher-
ence had low and equivalent mortality in the test and placebo arms, whereas poor adherers did
better in the test arm [6]. Still, understanding trial outcomes among participants who take
drugs as prescribed (i.e., a “per protocol [PP] analysis”) has some appeal, even though such an
analysis is not protected by randomization. In recent TB treatment trials, adequate adherence
was defined by a threshold of 76%–80% of intended doses taken, to identify the PP population
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[7,8]. This is consistent with analytic practice in the reporting of the MRC trials (which defined
an “excessive interruption” with exclusion from the relapse analyses if less than approximately
77% of intended doses were received) [9] and with recent practice in prominent United States
TB control programs (e.g., New York City) [10].
A recent meta-analysis of three Phase III trials of fluoroquinolone-based 4-month TB treat-
ment regimens found that nonadherence was the single most potent factor associated with
unfavorable treatment outcome. The adjusted hazard ratios (aHRs) were 5.7 (95% CI 3.3–9.9)
for test arm participants who missed 10% or more of prescribed doses and 1.4 (95% CI 1.0–
1.9) for test arm participants who had less than 10% nonadherence, compared with partici-
pants who completed treatment without any missed doses; the aHRs were similar in the con-
trol arm participants (Table 1) [11]. The same trend was seen in PP analysis, which excluded
participants who failed to complete at least 75%–80% of intended doses.
Such a potent influence of nonadherence serves to emphasize the often-noted importance
of the quality of performance in noninferiority trials; it further suggests that PP analyses might
examine more than 1 threshold for nonadherence (e.g., 80% and 95%) to help in more robustly
assessing efficacy. A stronger analytic approach might evaluate the effect on trial outcomes of
baseline pre-randomization variables associated with poor adherence [12]; by definition, base-
line variables should be approximately balanced in large randomized trials, thereby not intro-
ducing bias in the assessment of outcomes.
Definitions and measures of adherence
Adherence refers to the completeness with which participants or patients follow medical
instructions. Because adherence can vary so greatly among different individuals, it can have an
important influence on treatment outcomes. Adherence more broadly may also involve
changes required by the protocol (e.g., in response to elevated liver function tests) that are not
active choices by the participant. In their recent review on this topic, Blaschke and colleagues
observe that adherence is a major source of variability affecting the outcome of TB therapy
[13]. Adherence, in turn, is affected by diverse individual and social factors [14]. Other sources
of variability include the formulation of the test medications, the prescribed dosing, and the
pharmacokinetics and pharmacodynamics of each agent employed, as well as key features of
the infecting Mycobacterium tuberculosis strains (for example, the minimal inhibitory concen-
trations of each drug employed), and inherent characteristics of the host patient (including
genetic determinants of drug metabolism, immunologic competence, and the architecture of
TB lesions). The latter sources of variability are already determined at the onset of therapy and
are therefore likely to be balanced between treatment arms by the process of randomization. In
contrast, adherence is subject to ongoing variability during treatment, which complicates its
effects. Although genetic factors affecting drug exposure should be comparable at randomiza-
tion, their impact may vary by the drugs used in each arm. The recent availability of electronic
methods for monitoring adherence has made it possible to measure adherence quite precisely;
Table 1. Pooled mITT analysis of 3 TB treatment-shortening trials showing impact of adherence on unfavorable outcome.
Test arms (4 months, with FQ) Control arms (6 months, no FQ)
Prescribed doses Unfavorable Total Unfavorable Total
Received 100% of prescribed doses 238 (18%) 1,348 85 (9%) 913
Received 90%–99% of prescribed doses 64 (22%) 288 37 (16%) 230
Received <90% of prescribed doses 15 (47%) 32 16 (37%) 43
Abbreviations: FQ, fluoroquinolones; mITT, modified intent-to-treat
https://doi.org/10.1371/journal.pmed.1002884.t001
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these novel methods have become the gold standard for compiling dosing histories. At least 3
aspects of adherence are specifically relevant to antituberculosis therapy [15]:
1. the total quantity of nonadherence (i.e., what proportion of doses are missed, in relation to
the total number of doses in the intended treatment regimen?);
2. the timing of nonadherence (i.e., does it occur at the outset of therapy, throughout therapy,
or primarily at the end of the intended course of therapy?); and
3. the intensity and patterns of nonadherence (i.e., are many consecutive doses missed, or are
missed doses distributed relatively evenly throughout the course of therapy?).
The third aspect in particular can exert an important influence upon drug pharmacokinet-
ics and thus may predispose to either loss of efficacy or emergence of drug resistance. Conse-
cutive lapses in dosing can lead to lower-than-usual peak drug concentrations and lower total
drug exposures, whereas extra doses can result in risk of toxicity due to higher-than-usual
peak concentrations and total exposures (the review by Blaschke and colleagues includes a fig-
ure that nicely illustrates these risks [13]). The term “forgiveness” of a regimen is intended to
reflect the impact of variable lapses in dosing. Although “forgiveness” was originally defined as
“the post dose duration of therapeutically effective drug action, minus the recommended inter-
val between doses” [13], the shift from action to no action is likely to be gradual and to vary
among patients.
In the circumstance of treatment for TB, several examples come readily to mind:
1. The work of Imperial and colleagues demonstrated the association of overall nonadherence
with the treatment outcome of short-duration fluoroquinolone-based regimens [11];
2. The timing of nonadherence is likely critical, because nonadherence in the presence of high
bacillary loads typically seen in the intensive phase is likely to have greater impact than the
same degree of nonadherence later during the continuation phase, when bacillary loads are
generally several logs lower; this is particularly an issue in the presence of immunosuppres-
sion, because bacillary multiplication will resume more rapidly when such patients become
nonadherent;
3. Similarly, a gap of several doses (i.e., intensity) would likely have greater impact in the pres-
ence of high bacillary loads, such as during the early intensive phase. Recent guidelines
have advised against the use of highly intermittent regimens for this reason, with substantial
supporting evidence [16].
There is thus an urgent need for improved measures and more sophisticated means of ana-
lyzing such patterns and types of nonadherence in relation to treatment outcomes. In Phase I
and Phase II studies, optimal adherence is imperative to make decisions on regimens to move
forward to late-stage development. In Phase III studies, the objectives would drive the decision
on adherence implementation and measurement. In both scenarios, there is a need to measure
and report adherence appropriately, to understand better the performance of the tested
interventions.
Methods for assessment of adherence
Currently available methods for assessing adherence are limited, but considerable work is
underway to develop better approaches (Table 2). Among methods that have been used in past
investigations are (1) clinic-based DOT, in which ingestion of each medication dose is
observed in clinic by a health worker, thereby allowing exact counting of each study dose given
or missed; (2) home-based DOT by a health worker, a community worker, or a family
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member; (3) adherence to the calendar of study visits; (4) patient self-reports of adherence; (5)
use of pill counts made at the time of study visits; (6) electronic bottle caps or similar methods
to quantify the number and time of opening of medication bottles; and (7) tests of blood,
urine, or other body materials for specific drugs or their metabolites.
Some methods offer direct demonstration of adherence, whereas others provide only indi-
rect readouts. Newer methods are currently under investigation, including the quantification
of drug levels in hair [17] and the measurement of changes in skin color associated with spe-
cific medications (e.g., rifamycins or clofazimine); these both indicate cumulative adherence
rather than dynamic patterns.
There were several early trials of interventions to improve adherence (with the goal of
achieving better outcomes), but the knowledge base overall remains sparse, and recent system-
atic reviews underline the need for further investigation and a substantially enlarged evidence
base [18]. Electronic methods for measuring or estimating adherence are increasingly avail-
able, and some TB programs and countries are moving forward rapidly with such digital tools,
Table 2. Strengths and weaknesses of methods for encouraging and/or assessing adherence.
Methods Description Strengths Weaknesses
Home-based or
work-based DOT by
HCW
Ingestion of each medication dose is observed and
recorded by an HCW at home/work.
Monitors adherence in real time;
convenience for patient.
Costc; patient confidentiality.
In clinic DOT by
HCW
Ingestion of each medication dose is observed and
recorded by an HCW at the clinic.
Monitors adherence in real time;
lower cost than home or work-
based DOT by HCW.
Inconvenience to patient; cost to health system.
Family member
DOT
Ingestion of each medication dose is observed and
recorded by a designated family member.
Convenience for patient; lower cost
versus DOT by health worker.
Confidence in the reports from family members; data
on real-time adherence not available unless
transmitted to HCW on a daily basis.
Live video DOT
[27,28]
Ingestion of each medication dose is videoed by
patient and observed by an HCW in real timea.
Monitors adherence in real time;
convenience for patient.
Cost (HCW review of live video; smartphone);
patient and HCW acceptability.
Recorded video
DOT
Ingestion of each medication dose is videoed by
patient and sent to HCW to be viewed latera.
Convenience for patient. Cost (HCW review; smartphone); patient and HCW
acceptability; depending on when videos are viewed,
may not monitor adherence in real time; privacy
concerns.
Direct monitoring:
1. Blood testing
Blood sample taken to measure plasma levels of
TB medications.
Direct measurement of dose
ingested.
Feasibility/logistics; cost; depends on timing of blood
sample relative to time of ingestion; limited time
window.
2. Urine testing Urine testing for drug metabolites (e.g., isoniazid). Direct measurement of dose
ingested.
Feasibility/logistics; cost; sensitivity may vary
depending on acetylator status; limited time window.
3. Swallowed pill
sensors [29]
Ingestible sensor embedded in TB medications.
Pill interacts with gastric acid, and a signal is
transmitted to adhesive monitor on patient, which
in turn transmits information to smartphone.
No reliance on sample collection. Cost; relies on patient wearing the adhesive monitor;
patient acceptability.
Indirect
monitoring, device
facilitated
Pill box [22]
Bottle cap [30]
Medications placed in pill box/bottle. Opening/
closing of box/bottle, a proxy for dose taken, is
documented in real time via SIM card.b
Monitors adherence in real time (if
pill box/bottle cap transmits); low
cost (relative to HCW DOT).
Pill box opening/bottle cap removal may not reflect
an ingestion of dose; nonopening may not reflect
noningestion of dose if medications are not stored in
box/bottle.
Indirect
monitoring, patient
facilitated
SMS text messages
Patient sends SMS message to HCW when a dose
has been ingested.
Monitors adherence in real time;
low cost.
Patient needs to be familiar with text messaging; text
message sent may not reflect an ingestion of dose;
nonreceipt of SMS may not reflect noningestion of
dose.
a HCW observation could be replaced by face recognition and motion-detection software.
b Non–real time use of pillbox also possible where data on pill box opening/closing are downloaded at regular intervals, at a pharmacy refill, for example.
c Costs are important for all modalities; these often vary by setting or country and vary for newer technologies.
Abbreviations: DOT, directly observed therapy; HCW, healthcare worker; SIM, subscriber identity module; SMS, short message service; TB, tuberculosis
https://doi.org/10.1371/journal.pmed.1002884.t002
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generating large quantities of data. Appropriate methods for pooling and analyzing these data
are needed, as are methods for linking information on adherence to individual pharmacoki-
netics and pharmacodynamics and to individual outcomes [19]. A recently published system-
atic review of newer digital technologies, including short message service (SMS), video-
observed therapy (VOT), and medication monitors (MMs), for TB treatment adherence iden-
tified few comparative studies for inclusion and concluded that the evidence on the effect of
digital technologies to improve TB care remained limited [20]. For the studies included in the
review, no statistically significant effect on treatment completion was identified when SMS
was added to standard care or when VOT was used as an alternative to in-person DOT. It was
noted that MMs increased the probability of cure (risk ratio 2.3, 95% CI 1.6–3.4) in one obser-
vational study [21] and in one trial, significantly reduced missed treatment doses relative to
standard care (adjusted means ratio 0.58, 95% CI 0.42–0.79) [22].
Overall, the systematic review concluded that more studies of better quality are needed for
the evaluation of technologies applicable to measuring and maximizing adherence. There are
also few studies that have assessed the accuracy of digital adherence technologies in measuring
ingestion of medication doses. A study in China assessed the MM box (box opening between 6
and 24 hours before urine sample taken) against detecting rifampicin in urine and found a sen-
sitivity of 99% and specificity of 95% [23]. In India, SMS responses (from the cellphone-based
monitoring system known as “99DOTS”) over a 48-hour period, indicating dose taken, were
compared with isoniazid detection in urine, and a sensitivity and specificity of 68% and 62%
were observed, respectively [24]. A recent randomized trial in the United Kingdom noted con-
siderable success in use of VOT to assure dosing, compared with traditional DOT [25]. Ade-
quate study designs for evaluating accuracy of adherence monitoring devices are critical to
provide realistic tests of performance. Bias may be introduced, for example, if patient knowl-
edge that a urine sample will be collected inflates adherence around the scheduled time. Unan-
nounced collections may mitigate this. Timing of collections throughout the full treatment
period may also be important, for example, if adherence drops later during treatment. The
recent technical consultation report on “Advances in Clinical Trial Designs for Development
of New TB Treatments” also strongly endorsed the need for further investigations in this
domain and noted that trials offer an excellent platform for substudies in these areas [26].
Evidence for the benefit of traditional DOT has not been entirely consistent, and its role
remains controversial [18,31,32]. Some investigators favor relatively strict application of in-
person DOT, whereas others feel this is excessive and does not contribute to achievement of
objectives in properly randomized and implemented trials. Some investigators favor imple-
mentation of non-family-member in-person DOT, whereas others feel it is more reasonable to
allow local determination of what types of adherence support would be most useful. Better
means to measure adherence and its association with outcomes would contribute usefully to
this discussion [15,16]. Some of the digital health approaches being assessed in pragmatic trials
may be combined with differentiated care; in this approach, for example, those identified as
poor adherers through the digital health measures are assisted further with more traditional
approaches to maximizing adherence, with actual observation by health workers in the most
extreme cases [25,33].
Likewise, there is no consensus on a single criterion for “clinically important” nonadher-
ence. Assessment of the degree of nonadherence that should be deemed “clinically important”
depends on multiple factors specific to each trial setting, including the component drugs of the
regimen, the dosing schedule, the pharmacokinetics of the individual drugs, and other risk fac-
tors and comorbidities that could influence the risk of treatment failure or relapse. Embedded
in this discussion is consideration of the concept of “forgiveness” of a regimen (i.e., as noted
previously, a reference to the types and levels of nonadherence that would not substantively
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alter the likelihood of treatment effectiveness of a regimen). Although it could be considered
that this aspect should be reflected in the regimen’s efficacy and requires no other adjustment,
it can be argued that this aspect should be considered in the determination of the noninferior-
ity margin [34]. Further, some note that in the rational design and composition of new TB reg-
imens, the “forgiveness” of a regimen for missing doses should be considered with
significantly greater deliberation than is currently common, particularly given that adherence
in practice will never be perfect.
Adherence and acquired drug resistance
Recently released WHO target regimen profiles (TRPs) for TB identify the barrier to emer-
gence of resistance as an important characteristic to address in the development of new drugs
and regimens [35]. The association of nonadherence with acquisition of drug resistance has
been well reviewed [36,37,38], but the mechanisms underlying the association remain largely
speculative [39]. In the WHO TRPs, it is suggested, based on expert opinion, that each compo-
nent of the regimen should permit no greater mutation rate (in unselected bacterial popula-
tions) than 1/107 mutations/bacterium/generation and that new resistance to one or more
drugs in the regimen should emerge in fewer than 2% of treatment courses when taken as pre-
scribed and when there is no preexisting resistance to the drugs in the regimen. This minimal
target is based on an acquired resistance rate of 0%–2% when 5 effective drugs are used in the
WHO-recommended multiply drug resistant (MDR) regimen [40]. The reality of reduced
adherence in the field, as compared with clinical trial settings, and the potential impact such
real-world usage of a regimen may have on risks for emergence of resistance need further
study, representing another outcome of interest in how much “forgiveness” a putative new reg-
imen may carry for missed doses.
Summary
In conclusion, medication adherence remains a critical, yet understudied, factor influencing
outcomes of TB therapy. Its importance has been recognized since the advent of effective anti-
tuberculosis therapy, and the vital role adherence plays in the conduct of TB clinical trials has
been further highlighted in contemporary clinical trials [11]. The growing importance of non-
inferiority trial designs and the challenge of interpreting PP analyses have focused more atten-
tion on the issue of precisely measuring adherence and adherence patterns. Adherence is
important in both superiority and noninferiority trials and in both intent-to-treat (ITT) and
per-protocol (PP) analyses; both should be performed, and both should assess the impact of
variation in adherence. Only recently has our ability to measure adherence improved. Novel
(in particular, electronic) methods for assessing and encouraging adherence hold promise, and
efforts to develop a robust evidence base to support them are growing. Our understanding of
the impact of nonadherence on key outcomes (treatment success, emergence of resistance) in
TB treatment trials is relatively modest but is also receiving increased attention from investiga-
tors. Continued development of more convenient, more reliable, and less costly means to
achieve high levels of adherence will serve both trials and programs well.
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